Comparative Efficacy and Safety of Tezepelumab and Dupilumab in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
Latest Information Update: 25 Jan 2022
At a glance
- Drugs Tezepelumab (Primary) ; Dupilumab
- Indications Asthma
- Focus Adverse reactions
- 27 Dec 2021 Status changed from not yet recruiting to completed.
- 30 Jun 2021 New trial record